Clinical Trials on Resectable Pancreatic Adenocarcinoma in South Africa

Total 984 results

Medical University of South Carolina

Completed

A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma Non-resectable

United States
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

Pancreatic Adenocarcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Stage IV Pancreatic Cancer AJCC v6 and v7

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Pancreatic Adenocarcinoma | Resectable Pancreatic Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Sky Foundation

Active, not recruiting

Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer

Pancreatic Adenocarcinoma | Borderline Resectable Adenocarcinoma of the Head of the Pancrease

United States, Canada
Australasian Gastro-Intestinal Trials Group
University of Sydney

Active, not recruiting

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With CEND-1/LSTA1 or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma (ASCEND)

Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer

Australia, New Zealand
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Pancreatic Cancer | Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Adenocarcinoma

United States, Canada
Lisata Therapeutics, Inc.

Completed

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

Australia
University of Louisville
Norton Healthcare

Withdrawn

Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer

Unresectable Pancreatic Cancer

United States
Gilead Sciences

Terminated

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

Previously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal Adenocarcinoma

United States
OncoSil Medical Limited

Completed

A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane (PanCO)

Unresectable Locally Advanced Pancreatic Carcinoma

United Kingdom, Belgium, Australia
University of Cape Town

Unknown

Self-expandable Metal Stents Versus Multiple Plastic Stents for Palliation of Biliary Obstruction

Biliary Stricture | Cancer of the Pancreas | Bile Duct Obstruction, Extrahepatic | Cancer of the Bile Duct

South Africa
Dana-Farber Cancer Institute
Patient-Centered Outcomes Research Institute; National Cancer Institute (NCI); Alliance for Clinical Trials in Oncology

Completed

Improving Informed Consent for Palliative Chemotherapy

Metastatic Colorectal Cancer | Metastatic Pancreatic Cancer | Unresectable Pancreatic Cancer

United States
Cancer Trials Ireland

Terminated

Plasma Biomarkers P-DAC, V1

Pancreatic Ductal Adenocarcinoma

Ireland
Pfizer

Terminated

Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i)

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Panbela Therapeutics, Inc.

Completed

Study of SBP-101 in Pancreatic Cancer

Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

United States, Australia
Carolyn Britten
Oncovir, Inc.

Completed

A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma

Metastatic Pancreatic Cancer

United States
NewLink Genetics Corporation

Completed

Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States
Pharmexa A/S
Syneos Health; ICON Clinical Research; ORION Clinical Services; CIRION Central... and other collaborators

Terminated

GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

Advanced Unresectable Pancreatic Cancer

United States, Spain, Australia, Netherlands, Belgium, Denmark, France, Ireland, Italy, Norway, Poland, Sweden
FibroGen

Active, not recruiting

Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced Pancreatic Cancer (LAPIS)

Pancreatic Cancer Non-resectable

United States, Canada, France, Germany, Spain, Korea, Republic of, Austria, Italy, China, Belgium, Israel, United Kingdom
Halozyme Therapeutics

Terminated

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Cholangiocarcinoma Non-resectable | Cholangiocarcinoma, Extrahepatic | Cholangiocarcinoma, Intrahepatic | Gallbladder Adenocarcinoma

United States, Korea, Republic of, Thailand
Gilead Sciences

Withdrawn

A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Carcinoid Tumor | Functioning Pancreatic Neuroendocrine Tumor | Intermediate Grade Lung Neuroendocrine Neoplasm | Locally Advanced Pancreatic Neuroendocrine Tumor | Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm | Low Grade Lung Neuroendocrine Neoplasm | Metastatic Digestive... and other conditions

United States
Amplia Therapeutics Limited

Recruiting

ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | PDAC

Australia, Korea, Republic of
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Unresectable Pancreatic Neuroendocrine Carcinoma

United States
BioNTech SE

Recruiting

Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic Adenocarcinoma

Pancreatic Cancer

United States
Panbela Therapeutics, Inc.

Recruiting

Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer (ASPIRE)

Pancreatic Cancer Metastatic | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV

United States, Belgium, Germany, Spain, Korea, Republic of, Australia, France, Italy, Austria, United Kingdom
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Clovis Oncology, Inc.

Completed

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

Metastatic Pancreatic Adenocarcinoma

United States, Belgium, Canada, Australia, United Kingdom, Germany, Italy, Argentina, Russian Federation, France, Brazil, Sweden, Norway, Netherlands, Ukraine
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Metastatic Small Intestinal Adenocarcinoma | Recurrent Small Intestinal Carcinoma | Unresectable Small Intestinal Carcinoma

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Terminated

High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Stage I Pancreatic Cancer AJCC v6 and v7 | Stage II Pancreatic Cancer AJCC v6 and v7

United States, Canada, Israel, Belgium
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (daNIS-1)

Metastatic Pancreatic Ductal Adenocarcinoma

Belgium, Finland, Taiwan, Australia, Germany, Spain, Italy, Austria, Czechia, Switzerland, Singapore, United Kingdom, United States, France
NantCell, Inc.

Completed

QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer

Pancreatic Cancer | Adenocarcinoma of the Pancreas | Metastatic Pancreatic Cancer

United States
SynCore Biotechnology Co., Ltd.

Completed

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

Pancreatic Adenocarcinoma | Metastatic Pancreas Cancer | Locally Advanced Pancreatic Cancer

United States, Korea, Republic of, Taiwan, France, Hungary, Israel, Russian Federation
OncoSil Medical Limited

Recruiting

FOLFIRINOX Versus OncoSil™ in Addition to FOLFIRINOX in Patients With Locally Advanced Pancreatic Adenocarcinoma (TRIPP-FFX)

Locally Advanced Pancreatic Cancer

Spain, Belgium, United Kingdom, Italy, Australia
Sanofi
Taiho Pharmaceutical Co., Ltd.

Terminated

S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen (S-1 Pancreas)

Neoplasm Metastasis | Pancreatic Neoplasm

United States, France, Canada, Brazil, Romania, Sweden, Tunisia, Austria, Denmark, Hungary, Peru, South Africa, Greece, Costa Rica, Israel, Guatemala, Panama
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma

Pancreatic Cancer | Metastatic Pancreatic Adenocarcinoma | Metastatic Pancreatic Cancer

United States, Korea, Republic of, Japan, China, France, Turkey, Italy, Australia, Brazil, Ireland, Mexico, Spain, Taiwan
Threshold Pharmaceuticals
PRA Health Sciences

Completed

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Pharmacyclics LLC.

Completed

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Metastatic Pancreatic Adenocarcinoma

Spain, Italy, Korea, Republic of, United States, Belgium, United Kingdom, Germany, France
National Cancer Institute (NCI)

Recruiting

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Malignant Solid Neoplasm | Stage IV Pancreatic Cancer AJCC v8 | Pancreatic Carcinoma | Stage IV Ovarian Cancer AJCC v8 | Ovarian Low Grade Serous Adenocarcinoma

United States
National Cancer Institute (NCI)

Completed

Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy (S1115)

Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Pancreatic Acinar Cell Carcinoma

United States
Pharmacyclics LLC.

Completed

Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Pancreatic Cancer | Exocrine Pancreatic Cancer | Ductal Adrenocarcinoma

United States
Onconova Therapeutics, Inc.
Academic GI Cancer Consortium (AGICC)

Completed

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (ONTRAC)

Metastatic Pancreatic Adenocarcinoma

United States, India, Russian Federation, Hungary, Ukraine
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Metastatic Pancreatic Ductal Adenocarcinoma

United States, China, Hungary, Taiwan, Belgium, Germany, Spain, Italy, Czechia, France, Japan, Switzerland, Australia, Israel, Korea, Republic of, Canada, Russian Federation, Slovakia, United Kingdom, Turkey, Sweden, Greece, Finland, ... and more
Multitude Therapeutics Inc.
Tigermed Consulting Co., Ltd

Recruiting

AMT-151 in Patients With Selected Advanced Solid Tumours

Ovarian Cancer | Ovarian Epithelial Cancer | Lung Adenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Triple Negative Breast Cancer | Advanced Solid Tumor | Endometrial Cancer | Advanced Cancer | Ovarian Clear Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial... and other conditions

China, Australia
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States

Clinical Trials on Resectable Pancreatic Adenocarcinoma in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations